Speed

Salts []
Amphetamine chlorphenoxyacetate

Amphetamine hemisulfate

Amphetamine hydrochloride

Amphetamine adipate

Amphetamine tartrate

Amphetamine phosphate

Amphetamine hemisaccharate

Amphetamine succinate

Molecular structure via molpic based on CDK

Physical properties []
Molecular mass	135.21 g/mol ^[1]
Density	0.913 at 77 °F (EPA, 1998) - Less dense than water; will float g/cm³ ^[1]
Appearance	Mobile liquid ^[1]
Odor	Amine odor ^[1]
Taste	Acrid, burning taste ^[1]
Melting point	25 °C ^[1]
Boiling point	392 to 397 °F at 760 mmHg (EPA, 1998) ^[1]
Decomposition	When heated to decomposition it emits toxic fumes of nitroxides. ^[1]
Solubility	Moderate solubility ^[1]
Predicted LogP	1.8 ^[1]

Structural Identifiers []
Molecular formula	C₉H₁₃N ^[1]
IUPAC name	1-phenylpropan-2-amine ^[1]
SMILES	CC(CC1=CC=CC=C1)N ^[1]
InChI	InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3 ^[1]
InChIKey	KWTSXDURSIMDCE-UHFFFAOYSA-N ^[1]

Pharmacokinetics[]
Elimination half-life	dextroamphetamine: 9 – 11 hours^[4]levoamphetamine: 11 – 14 hourspH-dependent: 7 – 34 hours
Duration of action	Immediate release dosing: 3 – 6 hours Extended release dosing: 8 – 12 hours

Toxicity []
LD_Lo	Rat: - intraperitoneal: 23 mg/kg - intravenous: 20 mg/kg Dog: - subcutaneous: 20 mg/kg Monkey: - subcutaneous: 20 mg/kg Rabbit: - subcutaneous: 20 mg/kg - intravenous: 25 mg/kg Guinea pig: - oral: 200 mg/kg - subcutaneous: 20 mg/kg - parenteral: 20 mg/kg
LD₅₀	Rat: - oral: 30 mg/kg - subcutaneous: 180 mg/kg Mouse: - oral: 21 mg/kg - intraperitoneal: 5500 μg/kg - subcutaneous: 15 mg/kg - intravenous: 15 mg/kg Mammal (species unspecified): - oral: 135 mg/kg - intraperitoneal: 65 mg/kg

Dosing[]

Insufflated []
Light	≤ 13.2 mg(518x - 25.4%)
Common	13.2 - 20 mg(635x - 31.2%)
Strong	20 - 30 mg(449x - 22%)
Heavy	30 - 44 mg(233x - 11.4%)
Extreme	44 mg +(202x - 9.9%)

Intravenous []
Light	≤ 25 mg(430x - 46.7%)
Common	25 - 30 mg(178x - 19.3%)
Strong	30 - 35 mg(165x - 17.9%)
Heavy	35 - 40 mg(75x - 8.1%)
Extreme	40 mg +(73x - 7.9%)

Sublingual []
Light	≤ 13.9 mg(2x - 40%)
Common	13.9 - 15 mg(1x - 20%)
Strong	15 - 37.5 mg(1x - 20%)
Heavy	37.5 - 45 mg
Extreme	45 mg +(1x - 20%)

Oral []
Light	≤ 17 mg(374x - 25.9%)
Common	17 - 30 mg(446x - 30.8%)
Strong	30 - 50 mg(305x - 21.1%)
Heavy	50 - 97 mg(178x - 12.3%)
Extreme	97 mg +(143x - 9.9%)

Intrarectal []
Light	≤ 40.7 mg(19x - 33.9%)
Common	40.7 - 70 mg(11x - 19.6%)
Strong	70 - 100 mg(15x - 26.8%)
Heavy	100 - 162.5 mg(5x - 8.9%)
Extreme	162.5 mg +(6x - 10.7%)

Statistically derived dosages via DBI-IGS

We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

Amphetamine

(Redirected from dextroamphetamine)

Amphetamine (also known as Amphetamine, Amfetamine, Desoxynorephedrine, Norephedrane, 1-Phenyl-2-aminopropane, Elastonon, Fenopromin, Phenedrine, β-Aminopropylbenzene or Propisamine) is a stimulant substance of the amphetamine class.

Chemistry

Salts []

Amphetamine is typically found in the form of its chlorphenoxyacetate, hemisulfate, hydrochloride, adipate, tartrate, phosphate, hemisaccharate and succinate salts.

Stereochemistry []

Amphetamine is a racemic mixture of the enantiomers

Stereoisomers
Dextroamphetamine Dextroamphetamine

Subjective effects []

Physical effects
Abnormal heartbeat Appetite suppression Dehydration Dry mouth Increased blood pressure Increased heart rate Increased libido Restless legs Shakiness Stamina enhancement Stimulation Teeth grinding Vasoconstriction

Cognitive effects
Analysis enhancement Cognitive euphoria Compulsive redosing Disinhibition Ego inflation Focus enhancement Increased music appreciation Mania Motivation enhancement Suggestibility suppression Thought acceleration Wakefulness

Anodyne Usernotes []
magnus / Amphetamine^[sulfate] via Oral and Insufflation	focus enhancement; music enhancement; wakefulness; insomnia; pupil dilation; little euphoria, suppression of hunger and thirst
0xea / Amphetamine^{[freebase][sulfate][hydrochloride]} via Oral, Insufflated, Intrarectal, Subcutaneous, Intramuscular, Intravenous, Inhaled, Vaporized and Sublingual at 10-50mg oral, 30-60mg insufflated, 30-90mg intrarectal, 10-35mg intramuscular, 15-50mg intravenous and 5mg sublingual	comeup: 1 minute intravenous and 25 minute subcutaneous duration: 3-4 hours intravenous moderate stimulation; moderate euphoria; strong vasoconstriction

Legal status []

Australia: Amphetamine is a Schedule 8 substance.
Brazil: Amphetamine is a A3 substance.
Canada: Amphetamine is a Schedule I substance.
Germany: Amphetamine is a Anlage III substance.
New Zealand: Amphetamine is a Class B substance.
United Kingdom: Amphetamine is a Class B substance.
United States: Amphetamine is a List of Schedule II controlled substances (U.S.)|Schedule II substance.^[3]
United Nations: Amphetamine is a Schedule II substance.

References []

National Center for Biotechnology Information. PubChem Compound Summary for CID 3007, Amphetamine. Accessed October 15, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/3007
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Amphetamine. UNII: CK833KGX7E. Global Substance Registration System. Accessed October 15, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/CK833KGX7E
Ingersoll J. Amphetamine, Methamphetamine, and Optical Isomers. Bureau of Narcotics and Dangerous Drugs}. July 7, 1971. Accessed October 15, 2025. https://archives.federalregister.gov/issue_slice/1971/7/7/12730-12734.pdf
Adderall- dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet. Teva Pharmaceuticals USA, Inc.. November 8, 2019. Accessed October 15, 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81

Anodyne